{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,25]],"date-time":"2024-07-25T21:08:08Z","timestamp":1721941688033},"reference-count":41,"publisher":"Public Library of Science (PLoS)","issue":"2","license":[{"start":{"date-parts":[[2016,2,12]],"date-time":"2016-02-12T00:00:00Z","timestamp":1455235200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0149562","type":"journal-article","created":{"date-parts":[[2016,2,12]],"date-time":"2016-02-12T13:59:26Z","timestamp":1455285566000},"page":"e0149562","update-policy":"http:\/\/dx.doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":1,"title":["Is Abnormal Urine Protein\/Osmolality Ratio Associated with Abnormal Renal Function in Patients Receiving Tenofovir Disoproxil Fumarate?"],"prefix":"10.1371","volume":"11","author":[{"given":"Jasmine R.","family":"Marcelin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melody L.","family":"Berg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eugene M.","family":"Tan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hatem","family":"Amer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathan W.","family":"Cummins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stacey A.","family":"Rizza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2016,2,12]]},"reference":[{"issue":"2","key":"ref1","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1097\/MAJ.0b013e31812e6b34","article-title":"Prevalence of chronic kidney disease in an urban HIV infected population","volume":"335","author":"SK Fernando","year":"2008","journal-title":"Am J Med Sci"},{"issue":"6","key":"ref2","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1111\/j.1468-1293.2009.00693.x","article-title":"Factors associated with renal dysfunction within an urban HIV-infected cohort in the era of highly active antiretroviral therapy","volume":"10","author":"ET Overton","year":"2009","journal-title":"HIV Med"},{"issue":"1","key":"ref3","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/j.1468-1293.2010.00855.x","article-title":"Evaluation of glomerular filtration rate in HIV-1-infected patients before and after combined antiretroviral therapy exposure","volume":"12","author":"F Tordato","year":"2011","journal-title":"HIV Med"},{"issue":"10","key":"ref4","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1681\/ASN.2012080857","article-title":"Tenofovir effect on the kidneys of HIV-infected patients: a double-edged sword?","volume":"24","author":"J Tourret","year":"2013","journal-title":"J Am Soc Nephrol"},{"key":"ref5","unstructured":"Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Sections C1\u2013C4 and E1\u2013E13. Department of Health and Human Services [serial on the Internet]. Available from: Available at: <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/aidsinfo.nih.gov\/guidelines\/html\/1\/adult-and-adolescent-treatment-guidelines\/0\" xlink:type=\"simple\">http:\/\/aidsinfo.nih.gov\/guidelines\/html\/1\/adult-and-adolescent-treatment-guidelines\/0<\/ext-link>."},{"issue":"12","key":"ref6","doi-asserted-by":"crossref","first-page":"e174","DOI":"10.1086\/379829","article-title":"Tenofovir-related Fanconi syndrome with nephrogenic diabetes insipidus in a patient with acquired immunodeficiency syndrome: the role of lopinavir-ritonavir-didanosine","volume":"37","author":"F Rollot","year":"2003","journal-title":"Clin Infect Dis"},{"issue":"9","key":"ref7","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1093\/infdis\/jit043","article-title":"Association between antiretroviral exposure and renal impairment among HIV-positive persons with normal baseline renal function: the D:A:D study","volume":"207","author":"L Ryom","year":"2013","journal-title":"J Infect Dis"},{"issue":"4","key":"ref8","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1089\/aid.2008.0202","article-title":"Progressive renal tubular dysfunction associated with long-term use of tenofovir DF","volume":"25","author":"E Kinai","year":"2009","journal-title":"AIDS Res Hum Retroviruses"},{"issue":"2","key":"ref9","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1086\/499048","article-title":"Tenofovir-associated acute and chronic kidney disease: a case of multiple drug interactions","volume":"42","author":"AE Zimmermann","year":"2006","journal-title":"Clin Infect Dis"},{"issue":"9","key":"ref10","doi-asserted-by":"crossref","first-page":"595","DOI":"10.2165\/00003088-200443090-00003","article-title":"Tenofovir disoproxil fumarate: clinical pharmacology and pharmacokinetics","volume":"43","author":"BP Kearney","year":"2004","journal-title":"Clin Pharmacokinet"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/1423-0127-20-61","article-title":"Depletion of the cellular antioxidant system contributes to tenofovir disoproxil fumarate\u2014induced mitochondrial damage and increased oxido-nitrosative stress in the kidney","volume":"20","author":"P Abraham","year":"2013","journal-title":"J Biomed Sci"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1155\/2011\/354908","article-title":"Tenofovir Nephrotoxicity: 2011 Update","volume":"2011","author":"B Fernandez-Fernandez","year":"2011","journal-title":"AIDS Research and Treatment"},{"issue":"6","key":"ref13","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1038\/labinvest.2011.48","article-title":"Tenofovir Renal Proximal Tubular Toxicity Is Regulated By OAT1 and MRP4 Transporters","volume":"91","author":"JJ Kohler","year":"2011","journal-title":"Laboratory investigation; a journal of technical methods and pathology"},{"issue":"7","key":"ref14","doi-asserted-by":"crossref","first-page":"e103055","DOI":"10.1371\/journal.pone.0103055","article-title":"Vitamin D deficiency aggravates nephrotoxicity, hypertension and dyslipidemia caused by tenofovir: role of oxidative stress and renin-angiotensin system","volume":"9","author":"D Canale","year":"2014","journal-title":"PLoS One"},{"issue":"5","key":"ref15","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1086\/655681","article-title":"Systematic review and meta-analysis: renal safety of tenofovir disoproxil fumarate in HIV-infected patients","volume":"51","author":"RD Cooper","year":"2010","journal-title":"Clin Infect Dis"},{"issue":"1","key":"ref16","doi-asserted-by":"crossref","first-page":"e29977","DOI":"10.1371\/journal.pone.0029977","article-title":"Renal function declines more in tenofovir- than abacavir-based antiretroviral therapy in low-body weight treatment-naive patients with HIV infection","volume":"7","author":"T Nishijima","year":"2012","journal-title":"PLoS One"},{"issue":"12","key":"ref17","doi-asserted-by":"crossref","first-page":"e80242","DOI":"10.1371\/journal.pone.0080242","article-title":"Low body weight in females is a risk factor for increased tenofovir exposure and drug-related adverse events","volume":"8","author":"C Gervasoni","year":"2013","journal-title":"PLoS One"},{"issue":"7","key":"ref18","doi-asserted-by":"crossref","first-page":"e22661","DOI":"10.1371\/journal.pone.0022661","article-title":"Impact of small body weight on tenofovir-associated renal dysfunction in HIV-infected patients: a retrospective cohort study of Japanese patients","volume":"6","author":"T Nishijima","year":"2011","journal-title":"PLoS One"},{"issue":"11","key":"ref19","doi-asserted-by":"crossref","first-page":"e0142491","DOI":"10.1371\/journal.pone.0142491","article-title":"Long-Term Follow-Up of Proteinuria and Estimated Glomerular Filtration Rate in HIV-Infected Patients with Tubular Proteinuria","volume":"10","author":"H Peyriere","year":"2015","journal-title":"PLoS One"},{"issue":"4","key":"ref20","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1093\/ndt\/gfh658","article-title":"Long-term renal safety of tenofovir disoproxil fumarate in antiretroviral-naive HIV-1-infected patients. Data from a double-blind randomized active-controlled multicentre study","volume":"20","author":"H Izzedine","year":"2005","journal-title":"Nephrol Dial Transplant"},{"issue":"2","key":"ref21","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1093\/jac\/dkn499","article-title":"Glomerular filtration rates in HIV-infected patients treated with and without tenofovir: a prospective, observational study","volume":"63","author":"G Guaraldi","year":"2009","journal-title":"J Antimicrob Chemother"},{"issue":"8","key":"ref22","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1089\/apc.2008.0232","article-title":"Renal function in patients with preexisting renal disease receiving tenofovir-containing highly active antiretroviral therapy in the HIV outpatient study","volume":"23","author":"B Young","year":"2009","journal-title":"AIDS Patient Care STDS"},{"issue":"5","key":"ref23","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1093\/jac\/dkr039","article-title":"Low incidence of renal impairment observed in tenofovir-treated patients","volume":"66","author":"EP O'Donnell","year":"2011","journal-title":"J Antimicrob Chemother"},{"issue":"11","key":"ref24","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1111\/j.1365-2036.2012.05093.x","article-title":"Renal tubular dysfunction during long-term adefovir or tenofovir therapy in chronic hepatitis B","volume":"35","author":"N Gara","year":"2012","journal-title":"Aliment Pharmacol Ther"},{"key":"ref25","article-title":"Clinical Practice Guideline for the Management of Chronic Kidney Disease in Patients Infected With HIV: 2014 Update by the HIV Medicine Association of the Infectious Diseases Society of America","author":"GM Lucas","year":"2014","journal-title":"Clinical infectious diseases: an official publication of the Infectious Diseases Society of America"},{"key":"ref26","article-title":"Recommendations for a public health approach","year":"2010"},{"issue":"4","key":"ref27","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1001\/jama.2014.8722","article-title":"Antiretroviral treatment of adult HIV infection: 2014 recommendations of the International Antiviral Society-USA Panel","volume":"312","author":"HF Gunthard","year":"2014","journal-title":"Jama"},{"issue":"4","key":"ref28","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1093\/ajcp\/100.4.419","article-title":"Protein-osmolality ratio for the quantitative assessment of proteinuria from a random urinalysis sample","volume":"100","author":"DM Wilson","year":"1993","journal-title":"Am J Clin Pathol"},{"issue":"3","key":"ref29","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1373\/clinchem.2012.184259","article-title":"The Kidney Disease Improving Global Outcomes (KDIGO) Guideline Update for Chronic Kidney Disease: Evolution not Revolution","volume":"59","author":"EJ Lamb","year":"2013","journal-title":"Clinical Chemistry"},{"key":"ref30","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney inter, Suppl. 2013;3:1\u2013150."},{"issue":"4","key":"ref31","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1373\/clinchem.2006.077180","article-title":"Expressing the Modification of Diet in Renal Disease Study equation for estimating glomerular filtration rate with standardized serum creatinine values","volume":"53","author":"AS Levey","year":"2007","journal-title":"Clin Chem"},{"key":"ref32","article-title":"Higher tenofovir exposure is associated with longitudinal declines in kidney function in women living with HIV","author":"SM Baxi","year":"2015","journal-title":"AIDS"},{"issue":"1","key":"ref33","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1097\/QAI.0b013e3181d05579","article-title":"Incomplete reversibility of tenofovir-related renal toxicity in HIV-infected men","volume":"55","author":"K Wever","year":"2010","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"2","key":"ref34","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1001\/jamainternmed.2014.6786","article-title":"Changes in glomerular kidney function among HIV-1-uninfected men and women receiving emtricitabine-tenofovir disoproxil fumarate preexposure prophylaxis: a randomized clinical trial","volume":"175","author":"KK Mugwanya","year":"2015","journal-title":"JAMA Intern Med"},{"issue":"5","key":"ref35","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1177\/1545109711406735","article-title":"Monitoring of Renal Function among HIV-Infected Patients Receiving Tenofovir in a Resource-Limited Setting","volume":"10","author":"S Kiertiburanakul","year":"2011","journal-title":"J Int Assoc Physicians AIDS Care (Chic)"},{"issue":"6","key":"ref36","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1097\/QAD.0b013e3283262a64","article-title":"Kidney tubular abnormalities in the absence of impaired glomerular function in HIV patients treated with tenofovir","volume":"23","author":"P Labarga","year":"2009","journal-title":"AIDS"},{"issue":"8","key":"ref37","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1097\/QAD.0000000000000628","article-title":"Nonalbumin proteinuria predominates in biopsy-proven tenofovir nephrotoxicity","volume":"29","author":"ME Sise","year":"2015","journal-title":"AIDS"},{"issue":"9987","key":"ref38","doi-asserted-by":"crossref","first-page":"2606","DOI":"10.1016\/S0140-6736(15)60616-X","article-title":"Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials","volume":"385","author":"PE Sax","year":"2015","journal-title":"Lancet"},{"issue":"1","key":"ref39","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1097\/QAI.0000000000000225","article-title":"Tenofovir alafenamide vs. tenofovir disoproxil fumarate in single tablet regimens for initial HIV-1 therapy: a randomized phase 2 study","volume":"67","author":"PE Sax","year":"2014","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"4","key":"ref40","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1097\/QAI.0000000000000618","article-title":"Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate in the First Protease Inhibitor-Based Single-Tablet Regimen for Initial HIV-1 Therapy: A Randomized Phase 2 Study","volume":"69","author":"A Mills","year":"2015","journal-title":"J Acquir Immune Defic Syndr"},{"key":"ref41","article-title":"Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral regimens for virologically suppressed adults with HIV-1 infection: a randomised, active-controlled, multicentre, open-label, phase 3, non-inferiority study","author":"A Mills","year":"2015","journal-title":"Lancet Infect Dis"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0149562","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,10,22]],"date-time":"2018-10-22T09:58:13Z","timestamp":1540202293000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0149562"}},"subtitle":[],"editor":[{"given":"Antonio Carlos","family":"Seguro","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2016,2,12]]},"references-count":41,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2016,2,12]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0149562","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,2,12]]}}}